Nutr Metab Cardiovasc Dis. 2026 Feb 11:104603. doi: 10.1016/j.numecd.2026.104603. Online ahead of print.
ABSTRACT
BACKGROUND AND AIM: Serum uric acid (SUA) is associated with cardiovascular disease (CVD) prognosis, and statins may modulate SUA levels. The purpose of this study is to investigate the prognostic value of SUA in statin-treated CVD patients.
METHODS AND RESULTS: This study included and evaluated a cohort of 2739 CVD participants taking statins in 10 NHANES cycles between 1999 and 2018. The primary endpoints were defined as all-cause mortality and cardiovascular mortality by linkage to national death records. Kaplan-Meier analysis compared survival across SUA levels, while restricted cubic splines (RCS) evaluated dose-response relationships. Evaluate the hazard ratio and 95% CI of all-cause and cardiovascular mortality in CVD patients and subgroups using a weighted Cox proportional hazards regression model. The median SUA of patients in the queue was 5.9 (4.9-7.1) mg/dl. During a median follow-up period of 74 months, 1167 all-cause death and 479 cardiovascular death were recorded. The highest SUA quartile had a significantly increased risk of developing the primary endpoint (P < 0.001), and the RCS showed a linear relationship between SUA levels and endpoint events (P < 0.001). In the LDL-C < 70 mg/dL subgroup, fully adjusted models showed SUA positively correlated with all-cause mortality (HR: 1.148, 95% CI: 1.021-1.291, P = 0.021) and cardiovascular mortality (HR: 1.229, 95% CI: 1.014-1.490, P = 0.036).
CONCLUSIONS: High SUA levels are associated with poor prognosis in CVD patients who achieve LDL-C control targets by taking statins. SUA is a potential indicator reflecting residual risk in CVD patients.
PMID:41935854 | DOI:10.1016/j.numecd.2026.104603